BIOLARGO, INC. 10-Q

Item 5. Other Information   During the three months ended June 30, 2022, we sold 406,140 shares of our common stock and received $72,000 in gross and net proceeds pursuant to our purchase agreement with Lincoln Park.   During the three and six months ended June 30, 2022, we sold 4,605,430 and 9,802,398 shares of our common stock and received $876,000 and $1,732,000 in gross and net proceeds from five and an aggregate sixteen accredited investors. These sales were made pursuant to an exemption from registration under Regulation D.   Item 6. Exhibits   See the Exhibit Index for a list of exhibits filed as part of this report and incorporated herein by reference.   Exhibit Index       Incorporated by Reference Herein Exhibit Number Exhibit Description Form File Date 3.1 Bylaws of BioLargo, Inc., as amended and restated Form 10-KSB 5/23/2003 3.2 Amended and Restated Certificate of Incorporation for BioLargo, Inc. filed March  16, 2007 Form 10-KSB 5/4/2007 3.3 Certificate of Amendment to Certificate of Incorporation, filed May 25, 2018 Pos Am 6/22/2018 3.4 Amended and Restated Articles of Incorporation of Clyra Medical Technologies, Inc. Form 8-K 1/6/2016 4.1 BioLargo, Inc. 2007 Equity Incentive Plan Form 10-QSB 11/19/2007 4.2 Amendment No. 1 to BioLargo 2007 Equity Incentive Plan Def 14C (Exhibit A) 5/2/2011 4.3 2018 Equity Incentive Plan Form S-8 6/22/2018 4.4 Stock Option Award Agreement under 2018 Equity Incentive Plan Form S-8 6/22/2018 4.5 Notice of Stock Option Grant under 2018 Equity Incentive Plan Form S-8 6/22/2018 4.6 Restricted Stock Unit Award Agreement under 2018 Equity Incentive Plan Form S-8 6/22/2018 4.7 Notice of Restricted Stock Unit Award under 2018 Equity Incentive Plan Form S-8 6/22/2018 4.8 Form of Stock Options issued in exchange for reduction in accounts payable. Form 10-K 3/31/2015 4.9 Promissory note issued by Clyra Medical to Scion Solutions dated September 26, 2018 Form 8-K 10/2/2018   35 Table of Contents   4.10 Revolving Line of Credit Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay Form 8-K 7/7/2020 4.11 Security Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay Form 8-K 7/7/2020 4.12 Revolving Line of Credit Note issued by Clyra Medical to Vernal Bay on June 30, 2020 Form 8-K 7/7/2020 4.13 Stock Purchase Agreement and Plan of Reorganziation dated September 26, 2018, with Scion Solutions, LLC Form 8-K 8/10/2018 4.14 Warrant issued in unit offerings Form 10-Q 8/14/2020 4.15 Amendment to $50,000 Convertible Note dated March 8, 2018 Form 10-K 3/30/2021 4.16 Warrant issued to $50,000 Convertible Noteholder on March 1, 2020 Form 10-K 3/30/2021 10.1 License Agreement to Clyra Medical Technologies, Inc., dated December 17, 2012 Form 8-K 1/6/2016 10.2 December 30, 2015 amendment to License Agreement with Clyra Medical Technologies, Inc. Form 8-K 1/6/2016 10.3 Escrow Agreement dated September 26, 2018 regarding Clyra/Scion transaction Form 8-K 10/2/2018 10.4 Closing Agreement dated December 17, 2018 between Clyra Medical and Scion Solutions Form 8-K 12/19/2018 10.5 Amendment dated June 30, 2020 to License Agreement with Clyra Medical Technologies, Inc. Form 8-K 7/7/2020 10.6 Amendment dated June 30, 2020 to Consulting Agreement dated December 30, 2015 between Clyra Medical and Beach House Consulting LLC Form 8-K 7/7/2020 10.7 Consulting Agreement dated December 30, 2015 with Beach House Consulting LLC Form 8-K 10/2/2018 10.8 Commercial Office Lease Agreement for 14921 Chestnut St., Westminster, CA 92683 Form 8-K 12/19/2018 10.9 Commercial Office Lease Agreement for Oak Ridge Tennessee Form 8-K 7/7/2020 10.10 Purchase Agreement, dated as of March 30, 2020 by and between BioLargo, Inc. and Lincoln Park Capital Fund, LLC. Form 8-K 3/31/2020   36 Table of Contents   10.11† 2021 Engagement Extension Agreement with CFO Form 8-K 3/19/2021 10.12 Agreement dated March 1, 2022, by and between Scion Solutions, LLC, Clyra Medical Technologies, Inc., and BioLargo, Inc. Form 8-K 3/3/2022 10.13 Agreement dated March 1, 2022, by and between Clyra Medical Technologies, Inc., and BioLargo, Inc. Form 8-K 3/3/2022 10.14† 2022 Engagement Extension Agreement with CFO Form 8-K 3/24/2022 31.1* Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934     31.2* Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934     32.1* Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.     101.INS** Inline XBRL Instance     101.SCH** Inline XBRL Taxonomy Extension Schema     101.CAL** Inline XBRL Taxonomy Extension Calculation     101.DEF** Inline XBRL Taxonomy Extension Definition     101.LAB** Inline XBRL Taxonomy Extension Labels     101.PRE** Inline XBRL Taxonomy Extension Presentation     104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).       * Filed herewith   ** Furnished herewith   † Management contract or compensatory plan, contract or arrangement   SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.   Date: August 15, 2022 BIOLARGO, INC.       By: /s/ DENNIS P. CALVERT       Dennis P. Calvert   Chief Executive Officer               Date: August 15, 2022   By: /s/ CHARLES K. DARGAN, II       Chief Financial Officer       37